idt-biologika.comCrawled Nov 15, 2026
By Pascal Vonlanthen, Bioprocess Specialist, Securecell AG and Navjyot Waghmare, Automation Expert, IDT Biologika
The Viral Vector Process Development & Manufacturing Summit addresses challenges in viral vector production, including process optimization, GMP scaling, and CDMO partnerships.
By This white paper explains the pitfalls in the development of oncolytic viruses and how to avoid them.
By Understanding critical influencing factors of hydrogen peroxide biodecontamination is the subject of this white paper.
IDT provides advanced analytical assays for new vaccines and cell and gene therapy products, supporting safety testing through a range of established and emerging methods.
IDT Biologika presents its services in cell and gene therapy, covering process design and clinical and commercial manufacturing. The session addresses challenges in AAV vector manufacturing using a platform-based approach to optimize timelines, costs, and efforts for clinical use.
The American Society of Gene and Cell Therapy (ASGCT) Annual Meeting is the premier event for professionals in the field of gene and cell therapy. It is a meeting place to lean about the latest scientific research and technologies and connect with like-minded people.
DCAT Week is the premier event held annually in New York City for companies engaged in the Global Bio/Pharmaceutical Manufacturing Value Chain.
IDT Biologika specializes in producing technically complex formulations, including biopharmaceuticals, vaccines, lyophilized compounds, and narcotics, across all development and manufacturing stages.
The page shares IDT Biologika’s latest company news and upcoming conference participation.
IDT Biologika, TEW & SK bioscience – Merging Strengths. Advancing Therapies.
IDT Biologika’s employees contribute to improving the quality of life for many people through vaccine and gene therapy development.
IDT Biologika develops vaccines and gene and immune therapeutics for infectious diseases, supporting clients in pioneering new therapies to protect global health.
The company has suddenly appeared on the radar of federal politicians, journalists, and the public for good reason, as the specialist in advanced vector vaccines has the knowhow, technology and capacity to manufacture and fill COVID-19 vaccines on a large scale. It only used to be pharmaceutical insiders that were aware of the company located … Continued
IDT Biologika is a global biologics contract development and manufacturing organization (CDMO) offering end-to-end services for vaccines, viral vectors, and aseptic filling of biologics. Its main facility in Dessau-Rosslau, Germany, provides GMP-compliant contract manufacturing.
IDT Biologika is a global CDMO for Viral Vaccines, Gene & Immun Therapeutics and aseptic Fill-Finish of Sterile Injectables.
IDT Biologika complies with U.S. Department of Health and Human Services regulations when involved in Public Health Service-funded research.